Montelukast Zentiva (Montelukast Sodium)

Montelukast sodium, the active ingredient in Montelukast Zentiva, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to treat asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Zentiva acts on the leukotriene pathway to manage chronic respiratory conditions.

- Asthma: improves long‑term control and reduces frequency of symptoms. - Allergic rhinitis: relieves nasal congestion, sneezing and itchy eyes. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelukast may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: non‑productive. - Nausea: occasional upset stomach. - Dizziness: transient light‑headedness. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema, or anaphylaxis. - Neuropsychiatric events: depression, mood changes, or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Blood dyscrasias: neutropenia or eosinophilia. - Severe skin reactions: Stevens‑Johnson syndrome.

Before prescribing Montelukast Zentiva, clinicians should consider several safety aspects.

- Liver impairment: assess hepatic function and adjust therapy if needed. - Neuropsychiatric monitoring: watch for mood changes, depression, or suicidal ideation. - Pregnancy: category B; discuss risks and benefits with the patient. - Acute asthma attacks: not indicated for immediate relief; use rescue inhalers instead. - Hypersensitivity: avoid in patients with known allergy to montelukast or excipients. - Store at below 25°C: keep in the original pack, protect from moisture.

Montelukast can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Rifampin: may significantly lower montelukast plasma concentrations. - Phenobarbital: can reduce drug exposure through enzyme induction. - Zafirlukast: concurrent use may increase risk of leukotriene‑related adverse effects.

Moderate Interactions (Monitor Closely): - Fluoxetine: may potentiate neuropsychiatric side effects. - Theophylline: monitor for enhanced bronchodilator effects. - Beta‑agonists: possible additive bronchodilation; observe clinical response.